捷強裝備(300875.SZ)與自然人毛劍春共設天津戎創
格隆匯 1 月 11日丨捷強裝備(300875.SZ)公佈,基於業務拓展需求,公司與自然人毛劍春共同出資設立天津戎創空勤裝備有限公司(“天津戎創”)。天津戎創註冊資本1000萬元人民幣,其中公司使用自有資金出資600萬元,佔天津戎創註冊資本的60%。
公司此次投資設立控股子公司,充分利用現有優勢進行資源整合,立足技術優勢和研發積累,主營機場安全設備設施,包括機場安全保衞設備設施、應急救援設備、機場地面保障設備設施等,契合公司構建“平戰一體的核化生防禦裝備全產業鏈”的發展戰略,有利於提升公司綜合實力和整體競爭力,符合公司和全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.